Colorectal cancer vaccines

British Journal of Surgery

Volumn 85, Issue 2, 1998, Pages 149-154

  Maxwell Armstrong, C A ^a   Durrant, L G ^a   Scholefield, J H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 17-1A ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; HEAT SHOCK PROTEIN; MONOCLONAL ANTIBODY; MUCIN; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; CANCER IMMUNOLOGY; CLINICAL TRIAL; COLORECTAL CANCER; GENE EXPRESSION; HUMAN; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; ONCOGENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; COLORECTAL NEOPLASMS; HEAT-SHOCK PROTEINS; HUMANS; MUCINS; ONCOGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 0031885359     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00704.x     Document Type: Review

References (65)

1. OPCS 1995 Mortality Statistics by Cause: England and Wales 1992. Series DH2. No. 20. London: HMSO.
2. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2, or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
3. Robins RA. T cell responses at the host-tumour interface. Biochim Biophys Acta 1986; 856: 289-305.
4. Lennox ES, Sikora K. Definition of human tumor antigens. In: McMichael, Fabre, eds. Monoclonal Antibodies in Clinical Medicine. London: Academic Press, 1982.
5. Gottlinger HG, Funke I, Johnson JP et al. The epithelial cell surface antigen 17-1A, a target for antibody mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47-53.
6. Reithmuller G, Schneider-Gadicke E, Shlimock et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343: 1177-83.
7. Lindenmann J, Jerne NK. Speculations on Ids and homo-bodies. Ann Immunol (Paris) 1974; 124: 171-84.
8. Chattopadhyay P, Starkey J, Morrow WJW, Raychaudhuri S. Murine monoclonal anti-idiotypic antibody breaks unresponsiveness and induces a specific antibody response to melanoma associated proteoglycan antigen in cyanomolgus monkeys. Proc Natl Acad Sci U S A 1992; 89: 2684-8.
9. Roitt IM, Cooke A, Male DK et al. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet 1981; i: 1041-5.
10. Nisonoff A, Lamoyi E. Implications of the presence of an internal image of the antigen anti-idiotypic antibodies: possible applications to vaccine production. Clin Immunol Immunopathol 1981; 21: 397-406.
11. Raychaudhuri S. Anti-idiotypic antibodies: an alternative approach to tumour immunotherapy. Indian J Exp Biol 1989; 27:671-80.
12. Stein KE, Soderstrom T. Neonatal administation of idiotype or anti-idiotype primes for protection against Escherichia coli K13 infection in mice. J Exp Med 1984; 160: 1001-11.
13. Bloem AC, Jurgens R, Eichmann K, Emmrich F. Human immune response to group A streptococcal carbohydrate (A-CHO) III. Comparison of the efficacies of anti-idiotypic antibody and of nominal antigen in the induction of IgM anti-A-CHO-producing B cells. Eur J Immunol 1988; 18: 1959-64.
14. Herlyn D, Lubeck M, Sears H, Koprowski H. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 1985; 85: 27-35.
15. Herlyn D, Ross AH, Koprowski H. Anti-idiotype antibodies bear the internal image of a human tumour antigen. Science 1986; 232: 100-2.
16. Herlyn D, Wettendorf M, Schmoll E et al. Anti-idiotype immunization of cancer patients. Modulation of the immune response. Proc Natl Acad Sci U S A 1987; 84: 8055-9.
17. Herlyn D, Benden A, Kane M et al. Anti-idiotype cancer vaccines: pre-clinical and clinical studies. In Vivo 1991; 5: 615-24.
18. Samonigg H, Wilders-Truschnig M, Loibner H et al. Immune response to tumour antigen in a patient with colorectal cancer after immunization with anti-idiotypic antibody. Clin Immunol Immunopathol 1992; 65: 271-7.
19. Fagerberg J, Hjelm A-L, Ragnhammer P et al. Tumour regression in monoclonal antibody treated patients correlates with the presence of anti-idiotypic reactive T lymphocytes. Cancer Res 1995; 55: 1824-7.
20. Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology 1989; 67: 525-30.
21. Denton GWL, Durrant LG, Hardcastle JD et al. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994; 57: 10-14.
22. Durrant LG, Buckley TJD, Denton GWL et al. Enhanced cell-mediated tumour killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994; 54: 4837-40.
23. Maxwell-Armstrong CA, Buckley TJD, Durrant LG et al. The anti-idiotypic monoclonal antibody 105AD7 increases lymphocyte infiltration within colorectal tumours. Br J Surg 1996; 83: 1650 (Abstract).
24. Maxwell-Armstrong CA, Durrant LG, Robins RA et al. The anti-idiotypic monoclonal antibody 105AD7 increases expression of the interleukin-2 receptor by lymphocytes within colorectal cancers. Immunology 1996; 89: 25 (Abstract).
25. Hardman N, Murray B, Zwicki M et al. Application of genetically engineered anti-CEA antibodies for potential immunotherapy of colorectal cancer. Int J Biol Markers 1992; 7: 203-8.
26. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen. Int J Cancer 1991; 48: 900-7.
27. Thompson JA, Grunert F, Zimmerman W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-66.
28. Conry RM, LoBuglio AF, Kantor J et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54: 1164-8.
29. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen cpitopes from patients immunized with recombinant vaccinia-cea vaccine. J Natl Cancer Inst 1995; 87: 982-90.
30. Foon KA, Chakraborty M, John WJ et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine. J Clin Invest 1995; 96: 334-42.
31. Durrant LG, Denton GWL, Jacobs E et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours. Int J Cancer 1992; 50: 811-16.
32. Conry RM, LoBuglio AF, Curiel DR. Phase I trial of a polynucleotidc anti-tumour immunity to human carcino-embryonic antigen in patients with metastatic colorectal cancer. Hum Gene Ther 1996; 7: 755-60.
33. Fagerberg J, Samanci A, Vi O et al. Recombinant carcino-embryonic antigen and granulocyte-macrophage colony-stimulating factor for active immunisation of colorectal cancer patients. J Immunother 1995; 18: 132-7.
34. Bevan MJ. Class discrimination in the world of immunology. Nature 1987; 325: 192-4.
35. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
36. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
37. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B cell lymphoma. Nat Med 1996; 2: 1038-41.
38. Kantor J, Irvine K, Abrams S et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52: 6917-25.
39. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen preservation accessory function and clinical relevance. Adv In Exp Biol 1993; 329: 1-9.
40. Young JW, Inaba K. Dendritic cells as adjuvants for Class I major histocompatibility complex-restricted anti-tumor immunity. J Exp Med 1996; 183: 7-11.
41. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein primed cytotoxic T lymphocytes against tumour antigen in vivo. J Exp Med 1996; 183: 317-22.
42. Gabrilovich DI, Nadaf S, Corak S et al. Dendritic cells in anti-tumor immune responses 2. Dendritic cells grown from bone marrow precursors, but not mature dendritic cells from tumour-bearing mice are effective antigen carriers in the therapy of established tumours. Cell Immunol 1996; 170: 111-19.
43. Zitzvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumours peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T-helper cell-associated cytokines. J Exp Med 1996; 183: 87-97.
44. Gjertsen MK, Bakka A, Breivik J et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic cancer patients carrying the corresponding ras mutation. Lancet 1995; 346: 1399-400.
45. Jung S, Schleusner HJ. Human T lymphocytes recognize a peptide of single point-mutated oncogenic ras proteins. J Exp Med 1991; 73: 273-6.
46. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T-lymphocytes and anti-tumour immunity with DNA vaccines expressing single T-cell epitopes. J Immunol 1996; 156: 2369-75.
47. Strouss GJ, Decker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 1992; 227: 57-92.
48. Fontenot JD, Tjandra N, Bu D et al. Biophysical characterization of one-, two- and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 1993; 53: 5386-94.
49. Itkowitz S, Kjeldsen T, Friera A. Expression of Tn, sialosyl Tn and T antigen in human pancreas. Gastroenterology 1991; 100: 1691-700.
50. Jerome KR, Bu D, Finn OJ. Expression of tumour associated epitopes on EBV immortalized B cells and Burkitts lymphoma transfected with epithelial mucin cDNA. Cancer Res 1992; 52: 5985-90.
51. Jerome KR, Barnd DL, Bendt KM et al. Cytotoxic T lymphocytes derived from patients with breast adenocarcinomas recognize an epitope present on the protein core of a mucin molecule, preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908-16.
52. Barnd DL, Lan M, Metzger R, Finn OJ. Specific MHC unrestricted recognition of tumour associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 1989; 86: 7159-63.
53. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a human mucin MUC-1 in sera from breast, pancreas and colon cancer. Cancer Res 1994; 54: 2856-60.
54. Gourevitch MM, von Mensdorff-Pouilly S, Litnivov SV et al. Polymorphic epithelial mucin (muc-1) containing circulating immune complexes in carcinoma patients. Br J Cancer 1995; 72: 934-8.
55. Pecher G, Finn OJ. Induction of cellular immunity in chimps to human tumour-associated mucin by vaccination with MUC-1 cDNA transfected Epstein Barr virus immortalized autologous B cells. Proc Natl Acad Sci U S A 1996; 93: 1699-704.
56. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinomas. J Surg Res 1996; 63: 298-304.
57. Reddish MA, MacClean GP, Poppema S et al. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69 + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42: 303-9.
58. Udono H, Srivastava PK. Heat shock protein 70 associated peptides elicit specific cancer immunity. J Exp Med 1993; 178: 1391-6.
59. Li Z, Srivastava PK. Tumour rejection antigen gp96/grp 94 is an ATPase: implications for protein folding and antigen presentation. EMBO J 1993; 12: 3143-51.
60. Rouse BT, Rollinghoff J, Warner NL. Anti θ serum induced suppression of the cellular transfer of tumour-specific immunity to syngeneic plasma cell tumour. Nature New Biol 1972; 238: 116-17.
61. Leclerc JC, Gomard E, Plata F et al. Cell-mediated immune reaction against tumours induced by oncornaviruses. Int J Cancer 1973; 11: 426-32.
62. Topalian SL, Rosenberg SA. Evidence for specific immune reactions against growing cancers in mice and men. In: DeVita, Hellman, Rosenberg, eds. Important Advances in Oncology. Philadelphia, Pennsylvania: JB Lippincott, 1990.
63. Srivastava PK, DeLeo AB, Old LJ. Tumour rejection antigens of chemically induced tumours of inbred mice. Proc Natl Acad Sci U S A 1986; 83: 3407-11.
64. Ullrich SJ, Robinson EA, Law LW et al. A mouse tumour-specific transplantation antigen is a heat shock related protein. Proc Natl Acad Sci U S A 1986; 83: 3121-5.
65. Palladino MA, Srivastava PK, Oettgen HF et al. Expression of a shared tumour-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res 1987; 47: 5074-9.